FDA

FDA
#Cell therapy #Cytokine Release Syndrome (CRS) #FDA #Orphan drugs #Poolbeg Pharma

Poolbeg granted FDA ODD for CRS cell therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Poolbeg Pharma’s POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (CRS). The FDA grants orphan status to support the development of medicines for rare disorders affecting less than 200,000… Read More

#News

#DDW Highlights podcast #European Commission #FDA #Regulatory

New DDW Highlights podcast: 19 May 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news highlights this time focus on two major regulatory agencies, in a week… Read More

#News

#European Commission #FDA #Regulatory

This week in drug discovery (12-16 May) 

News round-up for 12-16 May by DDW Senior Digital Content Editor Diana Spencer. Our news highlights this time focus on two major regulatory agencies, in a week that saw the European Commission (EC) launch a new fund designed to tempt US researchers to EU countries, and the US… Read More

#News

Human neuron
#Amyotrophic lateral sclerosis (ALS) #Early access #FDA #Neuroscience #Spinogenix

FDA okays access programme for ALS synaptic regenerative therapy

The Food and Drug Administration (FDA) has authorised Spinogenix to begin its Expanded Access Program (EAP) for SPG302 in the United States for people with amyotrophic lateral sclerosis (ALS) that meet programme eligibility criteria.  SPG302 is being developed as the first synaptic regenerative approach to treating ALS, with the potential… Read More

#News #Regulatory #Trending News

Epidermolysis bullosa patient has foot bandaged
#Abeona Therapeutics #Epidermolysis bullosa #FDA #Gene therapy

Gene therapy for severe skin disease secures historic approval

The US Food and Drug Administration (FDA) has approved Abeona Therapeutics’ Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel.  Zevaskyn is an autologous cell-based gene therapy for the treatment of wounds in adult and paediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).  “Today’s approval of Zevaskyn represents a… Read More

#News #Regulatory #Trending News

Neurons
#AAV #BlackfinBio #FDA #Gene therapy #Neurology #Orphan drugs #Paediatrics #Rare disease

FDA clears gene therapy trial for rare neurological disease

The US Food and Drug Administration (FDA) has cleared BlackfinBio’s Investigational New Drug (IND) application for a Phase I/II clinical trial of novel adeno-associated virus (AAV) gene therapy, BFB-101, in children with Hereditary Spastic Paraplegia Type 47 (SPG47).  The trial will be conducted in the US at Boston Children’s Hospital… Read More

#News #Regulatory

FDA
#FDA #Neurology #Rare disease #Recordati

FDA grants label expansion for Cushing’s disease treatment

The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia.  It is now approved in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative.   This is an expansion of… Read More

#News #Regulatory

Bladder cancer
#AstraZeneca #Bladder cancer #FDA #Monoclonal antibodies #Oncology

Imfinzi approval a ‘breakthrough’ for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).  It is approved in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder). … Read More

#News #Regulatory

Leukaemia
#Acute Myeloid Leukaemia #FDA #Haematology #Oncology #Pleco Therapeutics

Positive FDA outcome for PTX-252 in acute myeloid leukaemia

Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, has announced a positive outcome from its Pre-Investigational New Drug (Pre-IND) meeting with the US Food and Drug Administration (FDA).   The meeting addressed the continued development of PTX-252, an intravenous (IV) formulation designed to treat patients with acute… Read More

#News #Regulatory

#Fast Track designation #FDA #mRNA #Sanofi #Vaccines

Chlamydia vaccine candidate granted fast track designation

The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The decision was based on the potential of the vaccine candidate to address a serious condition and address an unmet public health need.  The chlamydia vaccine candidate… Read More

#News #Regulatory

Patient taking antibiotics
#Antibiotic resistance #Antibiotics #Antimicrobials #Bacteria #FDA #GSK #Urinary

New class of oral antibiotics for uUTIs gets FDA green light

The US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12 years, ≥40kg) with uncomplicated urinary tract infections (uUTIs).  It is approved to treat infections caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex,… Read More

#News #Regulatory

Eye
#Eye health #FDA #Neuropathic corneal pain #OKYO Pharma

Neuropathic corneal pain treatment filed with FDA

OKYO Pharma, a clinical-stage biopharmaceutical company developing therapies for the treatment of neuropathic corneal pain and inflammatory dry eye disease has filed an application for Fast Track designation with the US Food and Drug Administration (FDA) for urcosimod (formerly known as OK-101). The company intends to use urcosimod for the… Read More

#News

Structure of the eye
#Cell therapy #FDA #Neurodegenerative disorders #Neurotech Pharmaceuticals #Ophthalmology

FDA approves first treatment for Macular Telangiectasia Type 2

The US Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel).  MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly impacting patients' quality of life.   Encelto utilises an encapsulated cell therapy… Read More

#News #Regulatory

#FDA #Health Canada #North America

New DDW Highlights podcast: 24 February 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following the news of cuts to medical research funding from the National Institutes of Health… Read More

#News

#FDA #Health Canada #North America

This week in drug discovery (17-21 February) 

News round-up for 17-21 February by DDW Senior Digital Content Editor Diana Spencer. Following the news of cuts to medical research funding from the National Institutes of Health (NIH), this week we focus on some positive drug discovery news from North America, including FDA priority review for… Read More

#News